Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-4016 in Advanced Solid Tumors or Lymphoma
NCT03168035Phase 1Completed
- Sponsor
- NanoCarrier Co., Ltd.
- Start
- Nov 2013
- Primary completion
- Apr 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NC-4016 in solid tumor (advanced stage) and lymphoma, sponsored by NanoCarrier Co., Ltd. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Nov 2013; status: completed.
02
Drugs
NC-4016
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT03168035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168035.